Nano Dimension to Merge with Infinite Epigenetics, Creating AI-Powered Preventive Health and Diagnostics Company
Key Insights
Nano Dimension and Infinite Epigenetics (search) announced a proposed stock-for-stock merger valuing Infinite at $890 million, with Nano shares valued at a 20% premium to estimated net cash at closing.
The combined company will leverage Infinite's proprietary biological AI platform, a CLIA-certified methylation laboratory, and a database of over 120,000 biological samples across a network of more than 7,500 healthcare providers.
Infinite's platform targets earlier and more precise chronic disease (search) detection through DNA methylation-based diagnostics, combining clinical testing, consumer longevity, pharma data, and enterprise health applications.
Nano Dimension Ltd. (search) (Nasdaq: NNDM) and Infinite Epigenetics (search) have provided additional details regarding their proposed business combination, a transaction that would transform the 3D printing technology company into a publicly traded, AI-powered preventive health and diagnostics enterprise. The update, issued June 16, 2026, follows the initial announcement on June 15 and addresses shareholder questions while outlining the strategic rationale behind the merger.
The stock-for-stock transaction values Infinite Epigenetics (search) at $890 million, with Nano Dimension shares valued at a 20% premium to estimated net cash at closing. Existing Nano shareholders will retain a meaningful minority stake in the combined company, which is expected to have over $400 million in cash at closing. Pre-combination shareholders will also receive contingent value rights tied to proceeds from legacy asset dispositions.
A Commercial Platform Built on Established Science
Infinite Epigenetics (search) is not a concept-stage company. It operates a CLIA-certified methylation laboratory capable of reading more than one million epigenetic signals from a single sample. Its proprietary database comprises more than 120,000 biological samples, placing it among the largest private DNA methylation datasets in the world. The company's network spans more than 7,500 healthcare providers, and its scientific foundation is supported by over 50 peer-reviewed publications authored by experts within its team.
The company's operating portfolio includes TruDiagnostic (search), a CLIA-certified laboratory and clinical epigenetic testing company, and Tally Health (search), a consumer longevity and preventive health business. This dual structure allows Infinite to pursue multiple revenue streams simultaneously: clinical diagnostics, consumer longevity testing, pharma data partnerships, and enterprise health applications.
"The science is established, not speculative," the companies stated. "Epigenetics is one of the most extensively validated areas of modern molecular biology."
Strategic Rationale and Market Opportunity
Nano Dimension's Board of Directors evaluated approximately 20 opportunities before selecting Infinite as the candidate offering the greatest potential for long-term value creation. The chronic disease (search) diagnostics market exceeds $90 billion, significantly larger than the 3D printing industry Nano previously served.
The Board drew parallels to three public-market leaders that have each validated different aspects of Infinite's model: GRAIL (approximately $2.5 billion market cap), which demonstrated methylation-based diagnostics can detect disease; Exact Sciences (search) (valued at approximately $21 billion in its announced acquisition by Abbott), which proved a molecular diagnostic test can achieve broad clinical adoption and payor reimbursement; and Tempus AI (approximately $9 billion market cap), which showed proprietary biological data paired with AI commands a premium public-market valuation.
Brad Keywell, an original investor and board member of Tempus AI, serves as Chairman of Infinite's board.
AI Strategy and Data Moat
Infinite's AI strategy centers on a multi-omics foundation model trained in biology rather than language. The company is developing a provider-facing assistant that helps clinicians interpret methylation reports, but the underlying value resides in the biological foundation model and proprietary dataset.
Unlike genetic testing, which returns the same fixed result, epigenetic testing is dynamic and longitudinal—a patient's biology changes over time, enabling repeat testing and creating a recurring revenue model. "Every repeat test feeds the model, making it smarter," the companies noted.
The capital from the transaction is expected to fund two complementary objectives: accelerating commercialization of Infinite's existing diagnostic and consumer operations, and expanding the proprietary methylation dataset to further develop the biological AI platform.
Governance and Shareholder Alignment
The combined company's board will include representatives from both entities, with Infinite designating up to five of seven members, including three independent directors. Nano Dimension will receive two board seats based on the expected shareholder ownership split.
The Board emphasized that the transaction provides no separate or transaction-driven compensation or payouts. Addressing shareholder feedback, the Board noted that a liquidation or wind-down would not return cash dollar-for-dollar due to wind-down costs, tax leakage, reserves for contingent liabilities, and extended escrow periods.
Transaction Timeline
A signed term sheet was executed on June 15, 2026, with a definitive agreement expected before July 31, 2026. The transaction remains subject to negotiation of definitive documents, shareholder approval, and customary closing conditions. Nano Dimension has committed to presenting the definitive agreement for a shareholder vote and will file a registration statement on Form S-4 containing a proxy statement and prospectus with the SEC.